Talking Medicines has set out how patient journey intelligence can help healthcare organisations develop care pathways that reflect both clinical requirements and the realities of living with a health condition. The approach strengthens the role of patient insight alongside established evidence sources, creating potential for more responsive care design and better-informed decision-making across the healthcare system.
A care pathway defines the recommended route through healthcare, covering symptom recognition, diagnosis, treatment and ongoing management. Its purpose is to promote consistency and ensure patients receive appropriate interventions at the right time. A patient journey, however, captures the personal experiences, decisions and challenges encountered while moving through that pathway.
The distinction is commercially and strategically relevant because a clinically sound pathway may not always operate as intended in practice. Patients may delay seeking help because they do not recognise symptoms, struggle to navigate referrals or feel uncertain when considering treatment options. Practical pressures, side effects and changing personal circumstances may also affect continued engagement with care.
Combining clinical pathways with patient journey intelligence can therefore provide a broader understanding of where barriers emerge and where additional support may be required. This creates opportunities to refine communication, education, service design and treatment support while reducing the risk that important patient needs remain hidden within conventional healthcare data.
Each stage of the patient journey presents different considerations. Early symptom recognition may involve uncertainty and information seeking through healthcare professionals, trusted sources and digital tools. Diagnosis can require multiple appointments, referrals and investigations, with variations in communication or coordination adding further complexity.
Treatment decisions may be shaped by more than clinical evidence alone. Patients can weigh potential benefits against side effects, lifestyle demands, personal circumstances and expectations for the future. Once treatment begins, medication management, work, family responsibilities and changes to daily routines become part of the experience. Long-term management adds another layer, as priorities and support needs can change over time.
These factors can be particularly important in rare diseases and multiple long-term conditions. Limited clinical experience, fragmented care and co-existing health issues can make pathways more difficult to navigate. Identifying these challenges earlier may support better allocation of resources and more targeted interventions.
Talking Medicines also emphasises that patient conversations can complement clinical trials, healthcare records and prescribing data. Traditional evidence remains essential, but it may not fully explain why patients seek medical advice, what shapes treatment decisions or where they feel unsupported. Patient insight can add context to these questions and help organisations understand how experiences evolve throughout the care pathway.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
